Table 3.

OS in patients who achieved CR and those who did not achieve CR

	Achieved CR		Did not achieve CR
	Glasdegib + LDAC n = 15	LDAC alone n = 1	Glasdegib + LDAC n = 63	LDAC alone n = 37
Median OS, months (95% CI)	26.1 (12.3–34.6)	12.9 (N/E–N/E)	5.0 (3.5–8.3)	4.1 (1.9–5.3)
Survival probability, % (95% CI)
6 months	100 (100–100)	100 (100–100)	49.5 (36.3–61.5)	31.5 (17.2–47.0)
12 months	86.7 (56.4–96.5)	100 (100–100)	27.3 (16.7–39.0)	5.7 (1.0–16.8)
Deaths, n (%)
Cause of death: disease under study	10 (66.7)	1 (100)	49 (77.8)	28 (75.7)

CI confidence interval, CR complete remission, LDAC low-dose cytarabine, N/E not evaluable, OS overall survival